Idorsia published its first quarter financial results 2023 on Tuesday April 25, 2023.

• Investor webcast
• Investor presentation
• Read the media release

Idorsia published its full year financial results 2022 on Tuesday February 7, 2023.

• Investor webcast
• Investor presentation
• Read the media release

Jean-Paul Clozel, CEO of Idorsia, presented at the 41^st J.P. Morgan Healthcare Conference 2023.

• Investor webcast
• Investor presentation
• Read the media release

In December 2022, Idorsia announced that the first patient has entered screening to participate in OPUS, a Phase 3 program to investigate the efficacy and safety of cenerimod, Idorsia’s novel, highly selective S1P₁ receptor modulator, as an oral treatment for adult patients with moderate to severe systemic lupus erythematosus.

• Investor webcast
• Investor presentation
• Read the media release

In November 2022, Idorsia announced the publication of “A randomized controlled trial of the dual endothelin antagonist aprocitentan for resistant hypertension” in The Lancet.

• Investor webcast
• Investor presentation
• Read the media release

Idorsia published its financial results for the first nine months of 2022 on Tuesday October 25, 2022.

• Investor webcast
• Investor webcast presentation
• Read the media release

Idorsia published its half year financial results 2022 on Tuesday
July 26, 2022.

• Investor webcast
• Investor webcast presentation
• Read the media release

In January 2022, Idorsia announced the publication of "Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials" in The Lancet Neurology.

• Webcast
• Read the media release
• Investor presentation

In June 2021, Idorsia announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y₁₂ receptor antagonist, in suspected acute myocardial infarction (AMI).

• Investor webcast
• Investor webcast presentation

The information in these investor webcasts was factually accurate at the time of broadcast. These webcasts remain on the Idorsia website for historical purposes only. Idorsia assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these presentations as current or accurate after their publication dates.